medigraphic.com

2008, Number 1

<< Back Next >>

Arch Cardiol Mex 2008; 78 (1)

Evaluation of the effect of Carvedilol in children with dilated cardiomyopathy

Balderrábano SNA, Vizcaíno AA, Espinosa IG, Reyes CL

Language: Spanish
References: 30
Page: 52-59
PDF size: 138.52 Kb.


ABSTRACT

Objective: To evaluate the effect of carvedilol administrated during 8 months in children with heart failure secondary to dilated cardiomyopathy. Methods: We initiated carvedilol in patients who, despite optimization of standard treatment, had persistent left ventricular ejection fraction £ 40% and evaluated the systolic and diastolic left ventricular function before and after 4 and 8 months of treatment. Results: 19 patients were included in the study, 10 women; median age: 6.7 years and 17 ± 12.4 months after the diagnosis. The ejection fraction improved significantly from entry to eight months (median: 33.5 to 52.6%, p = 0.01) as did the shortening fraction (m: 14.8 to 25.8%, p = 0.01). The myocardial performance index abnormal in all 19 patients became normal in 5 at the end of study. In addition mitral Doppler flow which was altered in 9 improved in 3 and pulmonary venous flow abnormal in all patients improved in 13. Only 1 patient presented minimal adverse effects. Conclusions: Carvedilol added to standard therapy for dilated cardiomyopathy improves left ventricular function, is well tolerated, and has minimal adverse effects in childhood.


REFERENCES

  1. Manolio TA, Baughman KL, Rodeneffer R, Pearson TA, Bristow JD, Michels VV, et al: Prevalence and etiology of idiopathic dilated cardiomyopathy (Summary of a National Heart Lung and Blood institute workshop). Am J Cardiol 1992; 69: 1458-66.

  2. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Herhberger RE, et al: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94: 2807-16.

  3. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto Ch: Cardioprotective effects o Carvedilol on acute autoinmmune myocarditis: anti-inflamatory effects associated with antioxidant property. Am J Physiol 2004; 286: 83-90.

  4. Bruns L, Kichuk M, Lamour J, Shaddy R, Pahl E, Blumme E, et al: Carvedilol as therapy in pedlatric heart failure: An initlal multicenter experience. J Pediatr 2001; 138: 505-11.

  5. Läer S, Mir Th, Behn F, Eiselt M, Scholz A, Meibohm B, et al: Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters. Am Heart J 2002; 143: 816-22.

  6. Rusconi P, Gómez-Marín O, Rossique-González M, Redha E, Marín J, Long-Young M, et al: Carvedilol in children with cardiomyopathy: 3-Year Experience at single institution. J Heart Lung Transplant 2004; 23: 832-838.

  7. Blume E, Canter C, Spicer R, Gauvreau K, Colan S, Jenkins K: Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 2006; 27: 336-342.

  8. Ross R: Grading the graders of congestive heart failure in children. J Pediatr 2001; 138: 618-20.

  9. Connolly D, Rutkowski M, Auslende M, Artman M: The New York University Pediatric Heart Failure index: new method of quantifying chronic heart failure severity in children. J Pediatr 2001; 138: 644-8.

  10. Schiller NB: Two dimensional Echocardiographic determination of left ventricular volume, systolic function and mass: summary and discussion of the 1989 recommendations of the American Society of Echocardiography. Circulation 1991; 84(Suppl): 1-280.

  11. Tomotsugu T, James D, Klein A: Pulmonary Venous Flow by Doppler Echocardiography: Revisited 12 Years Later. J Am Coll Cardiol 2003; 4: 1243-50.

  12. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al: New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function – a study in normals and dilated cardiomyopathy. J Cardiol 1995; 26(6): 357-66.

  13. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36.

  14. Chidsey CA, Harrison DC, Braunwald E: Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962; 267: 650-4.

  15. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Llang C, et al: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 1724-9.

  16. Cohn JN, Levine TB, Olivari MT, Gerberg V, Lura D, Francis GS, et al: Plasma norepinephrine as a guide to prognosis in patients with cronic congestive heart failure. N Engl J Med 1984; 311: 819-23.

  17. Yates JC, Beamish RE, Dhalla NS: Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecolamine cardiomyopathy. Am Heart J 1981; 102: 210-21.

  18. Sabbah HN: Apoptotic cell death in heart failure. Cardiovas Res 2000; 45: 704-12.

  19. Mann DL, Kent RL, Parsons B, Cooper G: Adrenergic effects on the biology of the adult mamallan cardiocyte. Circulation 1992; 85: 790-804.

  20. Packer M, Colucci WS, Sackner-Bernstein JD, Llang C, Goldscher DA, Freeman I, et al: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793-9.

  21. Kukin KL, Kalman J, Charney RH, Levy DK, Bucholz-Varley C, Ocampo ON, et al: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645-50.

  22. Lowes BD, Gill EA, Abraham WT, Larrain J-R, Robertson AD, Bristow MR, et al: Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83: 1201-5.

  23. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-6.

  24. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al: The effect of carvedilol on morbidity and mortality in patients with heart failure. N Engl J Med 1996; 334: 1349-55.

  25. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16.

  26. Packer M, Coats A, Fowler M, Katus H, Krum H, Mohacsi P, et al: Effect of carvedilol on survival in severe Chronical heart failure. N Engl J Med 2001; 344: 1651-1658.

  27. Packer M, Cohn JN: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83: 39A-42A.

  28. Shaddy R: B-Blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 1998; 136: 19-21.

  29. Shaddy R, Tani L, Gidding S, Pahl E, Orsmond G, Gilbert E, et al: Beta-blocker treatment of dilated cardiomyopathy in children: a multi-institutional experience. J Heart Lung Transplant 1999; 18: 269-74.

  30. Shaddy R, Leigh E, Sower B, Tani L, Burr J, LaSalle B, et al: The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design. Am Heart J 2002; 144: 383-389.




2020     |     www.medigraphic.com